NASDAQ:ARDX Ardelyx (ARDX) Stock Forecast, Price & News $3.76 +0.10 (+2.73%) (As of 11:40 AM ET) Add Compare Share Share Today's Range$3.62▼$3.8450-Day Range$3.40▼$4.8352-Week Range$1.09▼$5.13Volume2.67 million shsAverage Volume6.08 million shsMarket Capitalization$819.15 millionP/E RatioN/ADividend YieldN/APrice Target$8.25 ProfileProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaSustainabilityProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaSustainability Ardelyx MarketRank™ ForecastAnalyst RatingBuy3.00 Rating ScoreUpside/Downside116.0% Upside$8.25 Price TargetShort InterestHealthy11.83% of Shares Sold ShortDividend StrengthN/ASustainability-1.32Upright™ Environmental ScoreNews Sentiment0.64Based on 7 Articles This WeekInsider TradingSelling Shares$302,310 Sold Last QuarterProj. Earnings GrowthGrowingFrom ($0.38) to ($0.17) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.2.45 out of 5 starsMedical Sector193rd out of 965 stocksPharmaceutical Preparations Industry74th out of 450 stocks 3.5 Analyst's Opinion Consensus RatingArdelyx has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 6 buy ratings, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $8.25, Ardelyx has a forecasted upside of 116.0% from its current price of $3.82.Amount of Analyst CoverageArdelyx has only been the subject of 4 research reports in the past 90 days. Previous Next 3.0 Short Interest Percentage of Shares Shorted11.83% of the outstanding shares of Ardelyx have been sold short.Short Interest Ratio / Days to CoverArdelyx has a short interest ratio ("days to cover") of 5.Change versus previous monthShort interest in Ardelyx has recently decreased by 7.14%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldArdelyx does not currently pay a dividend.Dividend GrowthArdelyx does not have a long track record of dividend growth. Previous Next 4.4 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreArdelyx has received a 66.92% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is driven by its "Clinical research services for physical health" and "Constipation medication (A06)" products. See details.Environmental SustainabilityThe Environmental Impact score for Ardelyx is -1.32. Previous Next 3.7 News and Social Media Coverage News SentimentArdelyx has a news sentiment score of 0.64. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.54 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 7 news articles for Ardelyx this week, compared to 2 articles on an average week.Search Interest49 people have searched for ARDX on MarketBeat in the last 30 days. This is an increase of 63% compared to the previous 30 days.MarketBeat Follows18 people have added Ardelyx to their MarketBeat watchlist in the last 30 days. This is an increase of 125% compared to the previous 30 days. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Ardelyx insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $302,310.00 in company stock.Percentage Held by InsidersOnly 5.50% of the stock of Ardelyx is held by insiders.Percentage Held by Institutions58.19% of the stock of Ardelyx is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Ardelyx are expected to grow in the coming year, from ($0.38) to ($0.17) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Ardelyx is -13.17, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Ardelyx is -13.17, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioArdelyx has a P/B Ratio of 7.64. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Ardelyx (NASDAQ:ARDX) StockArdelyx, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines to treat gastrointestinal and cardiorenal therapeutic areas in the United States and internationally. The company's lead product candidate is tenapanor for the treatment of patients with irritable bowel syndrome with constipation. It also develops XPHOZAH, which is in Phase III clinical trial to control serum phosphorus in adult patients with chronic kidney disease (CKD)on dialysis, or hyperphosphatemia; RDX013, a potassium secretagogue, for the treatment of elevated serum potassium, or hyperkalemia, a problem among certain patients with kidney and/or heart disease; and RDX020, for adult patients with metabolic acidosis, a serious electrolyte disorder. The company has agreements with Kyowa Kirin, Fosun Pharmaceutical Industrial Development Co. Ltd., and Knight Therapeutics, Inc. for the development and commercialization of tenapanor in their respective territories. The company was formerly known as Nteryx, Inc. and changed its name to Ardelyx, Inc. in June 2008. Ardelyx, Inc. was incorporated in 2007 and is headquartered in Waltham, Massachusetts.Read More ARDX Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart ARDX Stock News HeadlinesSeptember 21, 2023 | americanbankingnews.comShort Interest in Ardelyx, Inc. (NASDAQ:ARDX) Drops By 7.1%September 19, 2023 | americanbankingnews.comArdelyx, Inc. (NASDAQ:ARDX) Given Average Recommendation of "Buy" by BrokeragesSeptember 22, 2023 | Behind the Markets (Ad)The single greatest medical breakthrough of all time?We are on the cusp of a medical breakthrough. And soon, this single breakthrough could lead to the cure of over 6,000 genetic diseases, including Alzheimer's, heart disease, and even cancer! This reminds me of Amgen, where early investors made as much as 46,751% when they released their revolutionary drug to the market.September 16, 2023 | americanbankingnews.comArdelyx, Inc. (NASDAQ:ARDX) to Post FY2023 Earnings of ($0.33) Per Share, Wedbush ForecastsSeptember 15, 2023 | americanbankingnews.comArdelyx's (ARDX) Outperform Rating Reaffirmed at WedbushSeptember 14, 2023 | msn.comWedbush Reiterates Ardelyx (ARDX) Outperform RecommendationSeptember 12, 2023 | markets.businessinsider.comAnalyst Expectations for Ardelyx's FutureSeptember 11, 2023 | markets.businessinsider.comArdelyx Showcased Encouraging Data on Treatment Satisfaction and Efficacy of IBSRELA® (tenapanor) for IBS-C at GHAPP 2023September 22, 2023 | Behind the Markets (Ad)The single greatest medical breakthrough of all time?We are on the cusp of a medical breakthrough. And soon, this single breakthrough could lead to the cure of over 6,000 genetic diseases, including Alzheimer's, heart disease, and even cancer! This reminds me of Amgen, where early investors made as much as 46,751% when they released their revolutionary drug to the market.September 11, 2023 | finance.yahoo.comArdelyx Showcased Encouraging Data on Treatment Satisfaction and Efficacy of IBSRELA® (tenapanor) for IBS-C at GHAPP 2023September 8, 2023 | benzinga.comArdelyx Stock (NASDAQ:ARDX), Analyst Ratings, Price Targets, PredictionsSeptember 8, 2023 | finance.yahoo.comArdelyx to Present at the H.C. Wainwright 25th Annual Global Investment ConferenceSeptember 8, 2023 | msn.comHC Wainwright & Co. Initiates Coverage of Ardelyx (ARDX) with Buy RecommendationSeptember 6, 2023 | finance.yahoo.comUnraveling Ardelyx Inc (ARDX): A Deep Dive into Its Performance MetricsSeptember 6, 2023 | finance.yahoo.comIs Ardelyx (ARDX) Too Good to Be True? A Comprehensive Analysis of a Potential Value TrapSeptember 1, 2023 | msn.comArdelyx (ARDX) Price Target Increased by 18.82% to 8.59August 25, 2023 | msn.comCantor Fitzgerald Upgrades Ardelyx (ARDX)August 25, 2023 | msn.comCantor upgrades Ardelyx to overweight ahead of FDA decision on renal drugAugust 25, 2023 | msn.comArdelyx (NASDAQ:ARDX) Jumps With Likely New Drug ApprovalAugust 15, 2023 | markets.businessinsider.comGrabar Law Office Investigates Claims on Behalf of Shareholders of Ardelyx Inc. (ARDX)August 10, 2023 | seekingalpha.comArdelyx, Inc. 2023 Q2 - Results - Earnings Call PresentationAugust 4, 2023 | finance.yahoo.comArdelyx, Inc. (NASDAQ:ARDX) Q2 2023 Earnings Call TranscriptAugust 3, 2023 | finance.yahoo.comForecast: Analysts Think Ardelyx, Inc.'s (NASDAQ:ARDX) Business Prospects Have Improved DrasticallyAugust 2, 2023 | markets.businessinsider.comArdelyx Q2 Loss NarrowsAugust 2, 2023 | finanznachrichten.deArdelyx, Inc.: Ardelyx Reports Second Quarter 2023 Financial Results and Provides 2023 IBSRELA Net Sales Revenue GuidanceAugust 2, 2023 | washingtonpost.comArdelyx: Q2 Earnings SnapshotAugust 2, 2023 | finance.yahoo.comArdelyx Reports Second Quarter 2023 Financial Results and Provides 2023 IBSRELA Net Sales Revenue GuidanceSee More Headlines Receive ARDX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Ardelyx and its competitors with MarketBeat's FREE daily newsletter. Email Address ARDX Company Calendar Last Earnings8/02/2023Today9/21/2023Next Earnings (Estimated)11/02/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:ARDX CUSIPN/A CIK1437402 Webwww.ardelyx.com Phone(510) 745-1700Fax510-745-0493Employees133Year Founded2007Price Target and Rating Average Stock Price Forecast$8.25 High Stock Price Forecast$10.00 Low Stock Price Forecast$7.00 Forecasted Upside/Downside+125.4%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage6 Analysts Profitability EPS (Most Recent Fiscal Year)($0.29) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-67,210,000.00 Net Margins-67.69% Pretax Margin-67.67% Return on Equity-54.22% Return on Assets-29.41% Debt Debt-to-Equity RatioN/A Current Ratio2.63 Quick Ratio2.50 Sales & Book Value Annual Sales$52.16 million Price / Sales15.29 Cash FlowN/A Price / Cash FlowN/A Book Value$0.50 per share Price / Book7.32Miscellaneous Outstanding Shares217,860,000Free Float205,881,000Market Cap$797.37 million OptionableOptionable Beta1.17 Social Links 12 Stocks Corporate Insiders are AbandoningIf a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know?Get This Free Report Key ExecutivesMr. Michael G. Raab (Age 58)Pres, CEO & Director Comp: $1.28MMs. Susan Rodriguez (Age 59)Chief Commercial Officer Comp: $760.77kDr. Laura A. Williams M.D. (Age 59)M.P.H., Chief Medical Officer Comp: $873.8kMr. Justin A. Renz CPA (Age 51)M.S.T., MBA, MST, Chief Financial & Operations Officer and Treasurer Mr. Robert FelschSr. VP of Fin. & Chief Accounting OfficerMs. Elizabeth A. Grammer Esq. (Age 59)Chief Legal & Admin. Officer and Sec. Ms. Caitlin LowieVP of Corp. Communications & Investor RelationsMs. Charon Spencer Sr.Chief HR OfficerMr. David P. Rosenbaum (Age 62)Chief Devel. Officer Mr. Robert C. Blanks (Age 63)Chief Regulatory Affairs & Quality Assurance Officer More ExecutivesKey CompetitorsPharming GroupNASDAQ:PHARTango TherapeuticsNASDAQ:TNGXCogent BiosciencesNASDAQ:COGTBelite BioNASDAQ:BLTEPliant TherapeuticsNASDAQ:PLRXView All CompetitorsInsiders & InstitutionsBarclays PLCBought 498,094 shares on 9/21/2023Ownership: 0.450%David P RosenbaumSold 2,897 sharesTotal: $13,181.35 ($4.55/share)Wolverine Trading LLCSold 14,300 shares on 8/23/2023Ownership: 0.000%Michael RaabSold 11,419 sharesTotal: $40,537.45 ($3.55/share)Susan RodriguezSold 4,733 sharesTotal: $16,802.15 ($3.55/share)View All Insider TransactionsView All Institutional Transactions ARDX Stock - Frequently Asked Questions Should I buy or sell Ardelyx stock right now? 6 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Ardelyx in the last twelve months. There are currently 6 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" ARDX shares. View ARDX analyst ratings or view top-rated stocks. What is Ardelyx's stock price forecast for 2023? 6 Wall Street analysts have issued 1 year price objectives for Ardelyx's stock. Their ARDX share price forecasts range from $7.00 to $10.00. On average, they anticipate the company's share price to reach $8.25 in the next twelve months. This suggests a possible upside of 125.4% from the stock's current price. View analysts price targets for ARDX or view top-rated stocks among Wall Street analysts. How have ARDX shares performed in 2023? Ardelyx's stock was trading at $2.85 at the beginning of 2023. Since then, ARDX stock has increased by 28.4% and is now trading at $3.66. View the best growth stocks for 2023 here. Are investors shorting Ardelyx? Ardelyx saw a decline in short interest during the month of August. As of August 31st, there was short interest totaling 25,770,000 shares, a decline of 7.1% from the August 15th total of 27,750,000 shares. Based on an average daily volume of 5,150,000 shares, the days-to-cover ratio is currently 5.0 days. View Ardelyx's Short Interest. When is Ardelyx's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, November 2nd 2023. View our ARDX earnings forecast. How were Ardelyx's earnings last quarter? Ardelyx, Inc. (NASDAQ:ARDX) released its quarterly earnings data on Wednesday, August, 2nd. The biopharmaceutical company reported ($0.08) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.12) by $0.04. The biopharmaceutical company had revenue of $22.33 million for the quarter, compared to analyst estimates of $15.88 million. Ardelyx had a negative trailing twelve-month return on equity of 54.22% and a negative net margin of 67.69%. What ETFs hold Ardelyx's stock? ETFs with the largest weight of Ardelyx (NASDAQ:ARDX) stock in their portfolio include SPDR S&P Biotech ETF (XBI) and Virtus LifeSci Biotech Clinical Trials ETF (BBC).Direxion Daily S&P Biotech Bull 3x Shares (LABU). What other stocks do shareholders of Ardelyx own? Based on aggregate information from My MarketBeat watchlists, some companies that other Ardelyx investors own include Micron Technology (MU), Dynavax Technologies (DVAX), Gilead Sciences (GILD), Rigel Pharmaceuticals (RIGL), Sorrento Therapeutics (SRNE), Inovio Pharmaceuticals (INO), NVIDIA (NVDA), Corbus Pharmaceuticals (CRBP), TherapeuticsMD (TXMD) and Advanced Micro Devices (AMD). What is Ardelyx's stock symbol? Ardelyx trades on the NASDAQ under the ticker symbol "ARDX." Who are Ardelyx's major shareholders? Ardelyx's stock is owned by a number of retail and institutional investors. Top institutional shareholders include State Street Corp (10.30%), BlackRock Inc. (6.44%), Geode Capital Management LLC (1.94%), Intrinsic Edge Capital Management LLC (1.13%), Woodline Partners LP (1.10%) and Northern Trust Corp (0.90%). Insiders that own company stock include David M Mott, David P Rosenbaum, Elizabeth A Grammer, Jeffrey W Jacobs, Justin A Renz, Laura A Williams, Michael Raab, Robert Blanks, Robert Ora Felsch, Scott D Sandell and Susan Rodriguez. View institutional ownership trends. How do I buy shares of Ardelyx? Shares of ARDX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Ardelyx's stock price today? One share of ARDX stock can currently be purchased for approximately $3.66. How much money does Ardelyx make? Ardelyx (NASDAQ:ARDX) has a market capitalization of $797.37 million and generates $52.16 million in revenue each year. The biopharmaceutical company earns $-67,210,000.00 in net income (profit) each year or ($0.29) on an earnings per share basis. How many employees does Ardelyx have? The company employs 133 workers across the globe. How can I contact Ardelyx? Ardelyx's mailing address is 34175 ARDENWOOD BOULEVARD SUITE 200, FREMONT CA, 94555. The official website for the company is www.ardelyx.com. The biopharmaceutical company can be reached via phone at (510) 745-1700, via email at investor@ardelyx.com, or via fax at 510-745-0493. This page (NASDAQ:ARDX) was last updated on 9/22/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Ardelyx, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.